ESR1 and breast carcinoma: In summary, it is expected that in FGFR-targeting therapies of ER+ breast cancer patients, simultaneous ER inactivation may produce synergistic therapeutic efficacy by reversing estragon-induced high FGFR1β/FGFR1α ratio in the ER+ breast cancer cells.